REAL-WORLD CASE STUDIES USING PURAPLY® AM

PuraPly AM[®] is an effective barrier to resist microbial colonization within the device and reduce microbes penetrating through the device.¹

Explore how PuraPly AM can take control of bioburden and biofilm re-formation to improve wound bed conditions and support healing in a wide range of wound types.¹⁻⁷





www.PuraPlyAM.com

TABLE OF CONTENTS

TAKE CON	TROL BEFORE BIOFILM RE-FORMS	2
BRIDGE BE	TWEEN DEBRIDEMENTS	3
TREATMEN	REATMENT ALGORITHM	
OVERVIEW	/ OF CASE STUDIES	5
CASE 1	Diabetic foot ulcer (DFU) with PuraPly® AM	6
CASE 2	Partial-thickness trauma wound with PuraPly AM	7
CASE 3	Heel pressure injury, which had failed a split-thickness skin graft, with PuraPly AM	8
CASE 4	Heel pressure injury with PuraPly AM	9
CASE 5	Surgical wound, which had failed a full-thickness skin graft, with PuraPly AM XT	10
CASE 6	Post-Mohs surgical wound (on right leg) with PuraPly AM XT transitioning to Affinity®	12
CASE 7	Post-Mohs surgical wound (on left leg) with PuraPly AM XT transitioning to Affinity	13
CASE 8	Venous leg ulcer (VLU) with PuraPly AM transitioning to Apligraf®	14
CASE 9	DFU with PuraPly AM transitioning to Apligraf	15
CASE 10	VLU with PuraPly AM transitioning to NuShield®	16
CASE 11	Trauma wound with PuraPly AM transitioning to NuShield	17

TAKE CONTROL BEFORE BIOFILM RE-FORMS


Use PuraPly[®] AM, an antimicrobial barrier, as early as day 1^{*} to help move wounds out of the inflammatory phase.^{1,4,8,9}

BIOFILM TRIGGERS NONSTOP INFLAMMATION THAT STALLS WOUNDS⁹⁻¹¹


MANAGE BIOFILM TO HELP CONTROL INFLAMMATION¹¹











BIOBURDEN & BIOFILM PROLONGED, ELEVATED INFLAMMATION

EXCESS MMPs

ECM DEGRADATION Sharp debridement should be combined with an optimal barrier that contains a broad-spectrum antimicrobial and provides a sustained effect against bioburden and biofilm regrowth.¹¹

*Certain local coverage determinations may not allow skin substitute use until after conventional care at week 4. MMPs = matrix metalloproteinases; ECM = extracellular matrix

BRIDGE BETWEEN DEBRIDEMENTS


Only PuraPly[®] AM, an antimicrobial barrier, combines native, cross-linked ECM plus broad-spectrum PHMB.¹



Scan to learn more about how PuraPly AM works.



Eliminates the need for at-home primary dressing changes^{1,2}



Helps prevent biofilm re-formation³

Keeps you in control of the healing environment

NATIVE, CROSS-LINKED ECM

Enhances resistance to enzymatic degradation^{12,13}




BROAD-SPECTRUM PHMB

Helps control bioburden³⁻⁶

TREATMENT ALGORITHM

Organogenesis—Elevating the standard of care with a broad portfolio of innovative solutions



are intended to be used as wound coverings and barriers

* E = **Exudate** well-controlled; I = No signs of clinical **Infection**; G = Healthy **Granulation** tissue present ⁺ Please refer to the Apligraf Package Insert for complete prescribing information and contraindications. VLU = venous leg ulcer; DFU = diabetic foot ulcer

OVERVIEW OF CASE STUDIES

Patient demographics and wound specifics


PATIENTS (n=10)	
MALES	4
FEMALES	6
MEAN AGE (YEARS)	73
AGE RANGE (YEARS)	53-96

	BASELINE WOUND AREA
MEAN	20.7 cm ²
MEDIAN	12.0 cm ²
RANGE	3.8-80.5 cm ²

BASELINE WOUND DURATION



Types of wounds (n=11)




PuraPly[®] AM, an antimicrobial barrier, supported healing of a DFU at 6 weeks following 5 applications

OUND SPECIFICS	PATIENT HISTORY		PRE	/IOUS TREATMENTS	PURAPLY AM APPLICATION S	CHEDU
time of PuraPly AM initiation pressure, and peripheral		heral neuropathy NPWT		Enzymatic debridement, NPWT, and Dermagraft [®] (1 application)	 Weekly applications for 5 weeks Offloading boot was used throughout the course of treatment 	
(3 months)	 Surgical history included NPWT; patient was previo 	or heumatoid arthritis OR debridement and		,		
1 st PuraPly AM application	2 nd PuraPly AN	A application	3 rd PuraPly	AM application	4 th PuraPly AM applic	ation
WEEK 1 Pre-debridement Date: 12/16/15 Wound Size: 3.8 x 3.9 x 0.5 cm	Vertication of the second seco	dement /23/15 5 x 3.3 x 0.1 cm	Pre-de Date: Wound Size:	VEEK 3 ebridement 12/30/15 1.8 x 2.9 x 0.1 cm	WEEK 4 Pre-debridement Date: 1/6/16 Wound Size: 1.3 x 2.0 x 0	
Wound Area: 14.8 cm ²	Wound Area		Wound . vound closure	Area: 5.2 cm ²	Wound Area: 2.6 cm	2
	WEEK 5				ЕК 12	
			1/20/16		2/29/16	
	debridement ate: 1/13/16	Date.	1/20/10	Date.	2,23,10	

6

PuraPly[®] AM, an antimicrobial barrier, supported healing of a partial-thickness trauma wound at 4 weeks following one application



PuraPly[®] AM, an antimicrobial barrier, supported healing of a heel pressure injury at 10 weeks following 9 applications, after failing a split-thickness skin graft (STSG)



PuraPly[®] AM, an antimicrobial barrier, supported healing of a heel pressure injury at 10 weeks following 9 applications

67-year-old male with a pressure injury on the left heel at the site of a previously closed wound				
WOUND SPECIFICS	PATIENT HISTORY	PREVIOUS TREATMENTS	PURAPLY AM APPLICATION SCHEDULE	
 Wound area was 18.0 cm² at the time of PuraPly AM initiation 	 Wound healing complicated by diabetes, neuropathy, and peripheral vascular disease 	NPWT	 Weekly applications for 9 weeks Offloading with total contact cast was used 	
 Wound recurrence was likely due to crow boot shearing while 	 Hypertension, gout, ESRD, hyperlipidemia, anemia, and osteomyelitis (right heel) 		throughout the course of treatment	
walking on right prosthesisWound was present for 9 weeks	Surgical history included partial calcanectomy bilaterally, right BKA, and surgical resection of left heel			

1st PuraPly AM application



WEEK 1

Pre-debridement Date: 6/29/15 Wound Size: 4.0 x 4.5 x 0.2 cm Wound Area: 18.0 cm²



Pre-debridement Date: 7/6/15 Wound Size: 3.7 x 4.2 x 0.2 cm Wound Area: 15.5 cm²



WEEK 2


WEEK 3 Pre-debridement Date: 7/13/15 Wound Size: 2.4 x 4.0 x 0.2 cm Wound Area: 9.6 cm²

4th PuraPly AM application



Pre-debridement Date: 7/20/15 Wound Size: 2.3 x 4.0 x 0.2 cm Wound Area: 9.3 cm²

5th PuraPly AM application



Pre-debridement Date: 7/27/15 Wound Size: 2.1 x 3.3 x 0.1 cm Wound Area: 6.9 cm²

6th PuraPly AM application



Pre-debridement Date: 8/3/15 Wound Size: 1.4 x 3.0 x 0.1 cm Wound Area: 4.2 cm²







WEEK 7


Pre-debridement Date: 8/10/15 Wound Size: 1.2 x 2.5 x 0.1 cm Wound Area: 3.0 cm²





Pre-debridement Date: 8/17/15 Wound Size: 0.7 x 2.1 x 0.1 cm Wound Area: 1.5 cm²

9th PuraPly AM application



Pre-debridement Date: 8/24/15 Wound Size: 0.2 x 0.7 x 0.1 cm Wound Area: 0.1 cm²

Complete wound closure



Date: 8/31/15

PuraPly[®] AM XT, an antimicrobial barrier, supported healing of a surgical wound at 6 weeks following 5 applications, after failing a full-thickness skin graft (FTSG)



CASE STUDIES UTILIZING PURAPLY® AM AND TRANSITIONING TO ANOTHER ORGANOGENESIS SOLUTION

PuraPly[®] AM XT, an antimicrobial barrier, transitioning to Affinity[®], a fresh amniotic membrane wound covering, supported healing of a post-Mohs surgical wound at 8 weeks

95-year-old female with a surgical wound on the right leg (same patient as on page 13) WOUND SPECIFICS PATIENT HISTORY PREVIOUS TREATMENTS PURAPLY AM XT APPLICATION SCHEDULE • Wound area was 10.5 cm² at the • Heart murmur, total hip replacement, and venous Xeroform and 2-laver • Weekly applications for 6 weeks time of PuraPly AM XT initiation insufficiency compression • Wound was present for 1 week Surgical history included Mohs surgery to remove a squamous cell carcinoma on the right leg Initial presentation 1st PuraPly AM XT application 2nd PuraPly AM XT application 3rd PuraPly AM XT application 1 week prior to PuraPly AM XT WEEK 1 WEEK 2 WEEK 3 Post-debridement Post-debridement Post-debridement Post-debridement Date: 5/26/21 Date: 6/2/21 Date: 6/11/21 Date: 6/16/21 Wound Size: 2.8 x 2.8 x 0.4 cm Wound Size: 3.0 x 3.5 x 0.5 cm Wound Size: 2.2 x 2.5 x 0.5 cm Wound Size: 2.2 x 2.5 x 0.5 cm Wound Area: 7.8 cm² Wound Area: 10.5 cm² Wound Area: 5.5 cm² Wound Area: 5.5 cm² 4th PuraPly AM XT application 5th PuraPly AM XT application 6th PuraPly AM XT application Transition to Affinity* **Complete wound closure** WEEK 4 WEEK 5 WEEK 6 WEEK 7 WEEK 8 Post-debridement Post-debridement Post-debridement Post-debridement 7/21/21 Date: 6/23/21 Date: 6/30/21 Date: 7/7/21 Date: 7/14/21 Patient received one Wound Size: 1.7 x 2.3 x 0.5 cm Wound Size: 1.2 x 1.4 x 0.5 cm Wound Size: 1.2 x 1.4 x 0.5 cm Wound Size: 0.4 x 0.2 x 0.2 cm application of Affinity. Wound Area: 3.9 cm² Wound Area: 1.7 cm² Wound Area: 1.7 cm² Wound Area: 0.08 cm² *Reduction in wound size with healthy granulation tissue and less slough.

Clinician transitioned to Affinity.


PuraPly[®] AM XT, an antimicrobial barrier, transitioning to Affinity[®], a fresh amniotic membrane wound covering, supported healing of a post-Mohs surgical wound at 7 weeks

NOUND SPECIFICS	PATIENT HISTORY	F	REVIOUS TREATMENTS PURAPLY A	M XT APPLICATION SCHEDULE	
Wound area was 3.8 cm ² at the time of PuraPly AM XT initiation Wound was present for 4 weeks	 Heart murmur, total hip replacement Surgical history included Mohs surge carcinoma on the left leg Patient underwent this procedure wh for another surgical wound on the rig 	ery to remove a basal cell F nile she was being treated	 Xeroform and oral antibiotic treatment prior to PuraPly AM XT application Weekly applications for 2 weeks 		
	Initial presentation	1 st PuraPly AM XT applica	tion 2 nd PuraPly AM XT application		
	3 weeks prior to PuraPly AM XT	WEEK 1	WEEK 2		
	Post-debridement	Post-debridement	Post-debridement		
	Date: 6/23/21 Wound Size: 2.8 x 2.7 x 0.3 cm Wound Area: 7.6 cm²	Date: 7/14/21 Wound Size: 1.9 x 2.0 x 0.7 c Wound Area: 3.8 cm ²	Date: 7/21/21 m Wound Size: 1.4 x 1.7 x 0.6 cm Wound Area: 2.4 cm ²		
Transition to Affinity	* 2 nd Affinity application	3 rd Affinity applicatior	No product application required	Complete wound closure	
WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	
Post-debridement Date: 7/28/21 Wound Size: 1.1 x 1.1 x 0.6 cm	Post-debridement Date: 8/4/21 Wound Size: 0.6 x 0.9 x 0.4 cm Wound Area: 0.5 cm ²	Post-debridement Date: 8/11/21 Wound Size: 0.5 x 0.8 x 0.4 c Wound Area: 0.4 cm ²	Post-debridement Date: 8/18/21 m Wound Size: 0.1 x 0.1 x 0.1 cm Wound Area: 0.01 cm ²	Date: 8/25/21	

PuraPly[®] AM, an antimicrobial barrier, transitioning to Apligraf[®], bioengineered with living cells, supported healing of a VLU at 12 weeks



PuraPly[®] AM, an antimicrobial barrier, transitioning to Apligraf[®], bioengineered with living cells, supported healing of a DFU at 13 weeks



PuraPly[®] AM, an antimicrobial barrier, transitioning to NuShield[®], a complete dehydrated placental allograft wound covering, supported healing of a VLU at 11 weeks



PuraPly[®] AM, an antimicrobial barrier, transitioning to NuShield[®], a complete dehydrated placental allograft wound covering, supported healing of a trauma wound at 16 weeks

69-year-old female with a trauma wound on the right lateral leg complicated by immunosuppressive therapy

WOUND SPECIFICS

- Wound was initially caused by trauma, was sutured but dehisced and became infected
- Wound area was 25.5 cm² at the time of PuraPly AM initiation
- Wound was present for 4 weeks

1st PuraPly AM application



WEEK1

Pre-debridement Date: 9/3/20 Wound Size: 8.5 x 3.0 x 0.5 cm Wound Area: 25.5 cm²

5th PuraPly AM application



Pre-debridement Date: 10/5/20 Wound Size: 7.0 x 3.0 x 0.1 cm Wound Area: 21.0 cm²

PATIENT HISTORY

- Wound healing was complicated by immunosuppressive therapy and venous insufficiency
- Patient was on several medications to treat rheumatoid arthritis including etanercept, leflunomide, and prednisone
- Hypertension, hyperthyroidism, and GERD

2nd PuraPly AM application



Pre-debridement Date: 9/11/20 Wound Size: 8.3 x 3.4 x 0.5 cm Wound Area: 28.2 cm²

6th PuraPly AM application

WEEK 6

Pre-debridement

Date: 10/12/20

Wound Size: 6.8 x 2.6 x 0.1 cm

Wound Area: 17.7 cm²



PREVIOUS TREATMENTS

Enzymatic debridement;

prior to PuraPly AM

initiation

oral antibiotics were used

to treat the wound infection

Pre-debridement Date: 9/16/20 Wound Size: 8.5 x 3.2 x 0.4 cm Wound Area: 27.2 cm²

Transition to NuShield*



Pre-debridement Date: 10/19/20 Wound Size: 6.2 x 2.5 x 0.1 cm Wound Area: 15.5 cm² Bioburden was well-managed. Clinician transitioned to NuShield.

4th PuraPly AM application

PURAPLY AM APPLICATION SCHEDULE

Weekly applications for 6 weeks

during PuraPly AM applications

Compression with Tubigrip was used



Pre-debridement Date: 9/25/20 Wound Size: 7.8 x 3.0 x 0.4 cm Wound Area: 23.4 cm²

Complete wound closure



Wound closed following 5 applications of NuShield.

PURAPLY® AM KEEPS YOU IN CONTROL



Give your patients the new standard of care.

Control bioburden right from the start and all week long with PuraPly AM, an effective barrier to resist microbial colonization within the device and reduce microbes penetrating through the device.¹⁷

Bioburden control as early as day 1 and all week long

Following sharp debridement, applying PuraPly AM as an antimicrobial barrier provides a foundation of care for weeklong control of bioburden and prevention of biofilm re-formation.¹⁻⁷

The unique power of plus for sustained control

Native, cross-linked ECM plus broad-spectrum PHMB acts as a bridge between weekly debridements by producing a sustained antimicrobial barrier effect.¹⁻⁴

Expanding evidence base of real-world clinical and scientific data

PuraPly AM gives you the confidence of control, with expanding clinical evidence in a variety of acute and chronic wounds and scientific data.^{3,7,18}

References: 1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020. 2. PuraPly XT Extra Fenestrated [package insert]. Canton, MA: Organogenesis Inc. 2020. 3. Davis SC, et al. Int Wound J. 2021;1-14. https://doi.org/10.1111/iwj.13600. 4. Brantley J, et al. Wounds Int. 2016;7(3):1-5. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715. 6. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
7. Bain MA, et al. J Comp Eff Res. 2020:9(10):691-703. 8. Carpenter S, et al. Wounds. 2016;28(6 suppl):S1-S20.
9. Frykberg RG, Banks J. Adv Wound Care. 2015;4(9):560-582. 10. Gibson D, et al. Wounds Int. 2009;1(1):1-6.
11. Schultz G, et al. Wound Repair Regen. 2017;25(5):744-757. 12. Khor E. Biomaterials. 1997;18(2):95-105.
13. Billiar K, et al. J Biomed Mater Res. 2001;56(1):101-108. 14. Phillips TJ, et al. J Am Acad Dermatol. 2000;43(4):627-630. 15. Gelfand JM, et al. J Invest Dermatol. 2002;119(6):1420-1425. 16. Sheehan P, et al. Jiabetes Care. 2003;26(6):1879-1882. 17. Attinger CE, et al. Plast Reconstr Surg. 2006;117(Suppl):72S-109S.
18. Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7:e2047.

